The propensity for the UK Department of Health, NHS England, the NHS Confederation and the National Audit Office (NAO), among others, to issue weighty updates that measure the distance travelled – and yet to go – on the healthcare excellence journey, is always impressive, often salutary, sometimes concerning.
The propensity for the UK Department of Health, NHS England, the NHS Confederation and the National Audit Office (NAO), among others, to issue weighty updates that measure the distance travelled – and yet to go – on the healthcare excellence journey, is always impressive, often salutary, sometimes concerning.
In the last few weeks, we have seen:
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
